The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
暂无分享,去创建一个
S. Gopal | U. Richarz | C. Benson | D. Najarian | Steven Wang | Paola M. López Rengel | J. Kane | R. Milz | Karl Knight | José Antunes
[1] T. Furukawa,et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis , 2022, The Lancet.
[2] C. Correll,et al. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach , 2022, BMC Psychiatry.
[3] M. García-Portilla,et al. Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study , 2022, Expert opinion on pharmacotherapy.
[4] L. Citrome,et al. Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study , 2022, Patient preference and adherence.
[5] David Taylor,et al. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study. , 2022, Journal of psychiatric research.
[6] J. McEvoy,et al. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia , 2021, CNS Drugs.
[7] P. Mavros,et al. Correction to: Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis , 2021, CNS Drugs.
[8] A. Tanskanen,et al. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. , 2021, Schizophrenia bulletin.
[9] N. Tandon,et al. Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters , 2021, Journal of health economics and outcomes research.
[10] T. Kishimoto,et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. , 2021, The lancet. Psychiatry.
[11] O. Tcheremissine,et al. The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study , 2021, Advances in Therapy.
[12] R. Lencer,et al. Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. , 2021, Comprehensive psychiatry.
[13] P. Lefebvre,et al. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries with Prior Schizophrenia Relapse. , 2021, Clinical therapeutics.
[14] P. Lefebvre,et al. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate , 2021, Current medical research and opinion.
[15] Edward Kim,et al. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study , 2021, Current medical research and opinion.
[16] S. Pappa,et al. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate , 2021, Therapeutic advances in psychopharmacology.
[17] A. Vita,et al. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia , 2020, BMC Psychiatry.
[18] OUP accepted manuscript , 2021, The International Journal of Neuropsychopharmacology.
[19] J. García-Carmona,et al. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain , 2020, International clinical psychopharmacology.
[20] J. Lieberman,et al. How mental health care should change as a consequence of the COVID-19 pandemic , 2020, The Lancet Psychiatry.
[21] P. Weiden,et al. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study , 2020, CNS Drugs.
[22] M. Mathews,et al. Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire , 2020, Patient preference and adherence.
[23] M. Mathews,et al. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies , 2020, Neuropsychiatric disease and treatment.
[24] Jessica M. Gannon,et al. Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions , 2020, Schizophrenia Research.
[25] P. Llorca,et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia , 2020, Therapeutic advances in psychopharmacology.
[26] L. Dima,et al. Long-acting injectable antipsychotics treatment during COVID-19 pandemic – A new challenge , 2020, Schizophrenia Research.
[27] O. Howes,et al. Schizophrenia-An Overview. , 2020, JAMA psychiatry.
[28] P. Lefebvre,et al. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate , 2019, Drugs - Real World Outcomes.
[29] Seung Woo Cho,et al. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study , 2019, European Neuropsychopharmacology.
[30] P. Czobor,et al. Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary , 2019, PloS one.
[31] C. Correll,et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia , 2019, Neuropsychiatric disease and treatment.
[32] J. Dilley,et al. Recovery-Oriented Outcomes Associated with Long-Acting Injectable Antipsychotics in an Urban Safety-Net Population , 2019, Community Mental Health Journal.
[33] A. Ballerini,et al. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia , 2019, Neuropsychiatric disease and treatment.
[34] M. Broder,et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data , 2019, Current medical research and opinion.
[35] P. Lefebvre,et al. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans , 2019, Current medical research and opinion.
[36] M. Bernardo,et al. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia , 2018, Expert opinion on pharmacotherapy.
[37] M. Broder,et al. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data , 2018, Advances in Therapy.
[38] B. Shiner,et al. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. , 2018, Clinical therapeutics.
[39] M. Byerly,et al. Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2 , 2018, Neuropsychiatric disease and treatment.
[40] P. Ferri,et al. Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting , 2018, Nordic journal of psychiatry.
[41] Yongling Xiao,et al. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics , 2018, Journal of medical economics.
[42] A. Tanskanen,et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia , 2017, Schizophrenia Research.
[43] M. Sajatovic,et al. A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness , 2017, Journal of clinical psychopharmacology.
[44] P. Bozzatello,et al. Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia , 2017, Neuropsychiatric disease and treatment.
[45] P. Lefebvre,et al. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. , 2017, Clinical therapeutics.
[46] P. Weiden,et al. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. , 2017, The Journal of clinical psychiatry.
[47] P. Lefebvre,et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting , 2017, Current medical research and opinion.
[48] Jingping Zhao,et al. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study , 2017, Neuropsychiatric disease and treatment.
[49] M. Mathews,et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies , 2017, npj Schizophrenia.
[50] P. Weiden,et al. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model , 2017, CNS Drugs.
[51] B. Shiner,et al. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. , 2016, The Journal of clinical psychiatry.
[52] Xiaoyun Pan,et al. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate , 2016, Current medical research and opinion.
[53] X. Haiyan,et al. PM511. Determinants of Caregiver Burden in Family Carers of Asian Patients with Schizophrenia treated with Paliperidone Palmitate 3-monthly injectable , 2016, International Journal of Neuropsychopharmacology.
[54] P. Rocca,et al. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life , 2016, Neuropsychiatric disease and treatment.
[55] W. Fleischhacker,et al. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study , 2016, The international journal of neuropsychopharmacology.
[56] L. Alphs,et al. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia , 2016, Schizophrenia Research.
[57] R. Risinger,et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. , 2015, The Journal of clinical psychiatry.
[58] Yanning Liu,et al. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial. , 2015, JAMA psychiatry.
[59] J. Lindenmayer,et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. , 2015, The Journal of clinical psychiatry.
[60] M. Mimura,et al. A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy , 2014, Human psychopharmacology.
[61] P. Weiden,et al. Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine: A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia , 2014, Journal of clinical psychopharmacology.
[62] David Taylor,et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal , 2014, Therapeutic advances in psychopharmacology.
[63] V. Cornelius,et al. Paliperidone palmitate long‐acting injection – prospective year‐long follow‐up of use in clinical practice , 2014, Acta psychiatrica Scandinavica.
[64] R. Rosenheck,et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. , 2014, JAMA.
[65] Lange Ap,et al. History and therapeutic rationale of long acting antipsychotics. , 2014 .
[66] A. de Risio,et al. History and therapeutic rationale of long acting antipsychotics. , 2014, Current clinical pharmacology.
[67] Hassan Khan,et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.
[68] Stephan Heckers,et al. Definition and description of schizophrenia in the DSM-5 , 2013, Schizophrenia Research.
[69] W. Fleischhacker,et al. Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective , 2013, CNS Drugs.
[70] J. Kane,et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia , 2013, Journal of medical economics.
[71] P. Fusar-Poli,et al. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis , 2013, Therapeutic advances in psychopharmacology.
[72] Erika P. Raven,et al. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia , 2012, Schizophrenia Research.
[73] R. Hansen,et al. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs. , 2012, Psychiatric services.
[74] Michael F. Green,et al. Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation , 2012, Schizophrenia Research.
[75] R. Hansen,et al. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. , 2012, The primary care companion for CNS disorders.
[76] E. Mundo,et al. Intramuscular Preparations of Antipsychotics , 2012, Drugs.
[77] Erika P. Raven,et al. Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory , 2011, Schizophrenia Research.
[78] J. Volavka,et al. Pathways to aggression in schizophrenia affect results of treatment. , 2011, Schizophrenia bulletin.
[79] S. Fazel,et al. Psychotic disorders and repeat offending: systematic review and meta-analysis. , 2011, Schizophrenia bulletin.
[80] J. Tiihonen,et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.
[81] S. Gopal,et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia , 2011, Journal of psychopharmacology.
[82] R. Rosenheck,et al. Criminal Justice System Involvement Among People with Schizophrenia , 2011, Community Mental Health Journal.
[83] S. Gopal,et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study , 2010, International clinical psychopharmacology.
[84] Josep Maria Haro,et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia , 2010, Psychiatry Research.
[85] J. Kane,et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. , 2010, The American journal of psychiatry.
[86] S. Gopal,et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study , 2010, Schizophrenia Research.
[87] B. Eriksson,et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden , 2010, The European Journal of Health Economics.
[88] David Taylor. Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review , 2009, British Journal of Psychiatry.
[89] Mark Taylor,et al. Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review , 2009, British Journal of Psychiatry.
[90] J. Lauriello,et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. , 2008, The Journal of clinical psychiatry.
[91] L. Hranov,et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.
[92] A. Fu,et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States , 2007, Current medical research and opinion.
[93] I. Glick,et al. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. , 2005, The Journal of clinical psychiatry.
[94] Jürgen Unützer,et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. , 2005, The American journal of psychiatry.
[95] P. Chue,et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets , 2005, European Neuropsychopharmacology.
[96] M. Knapp,et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life , 2004, British Journal of Psychiatry.
[97] E. Mundo,et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. , 2003, Drugs.
[98] Christian R. Dolder,et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. , 2002, The Journal of clinical psychiatry.
[99] L. Teplin. The prevalence of severe mental disorder among male urban jail detainees: comparison with the Epidemiologic Catchment Area Program. , 1990, American journal of public health.
[100] G. Klerman,et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. , 1980, Archives of general psychiatry.
[101] F. Quitkin,et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. , 1977, Archives of general psychiatry.